Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Apogee Therapeutics, Inc.NASDAQ: APGE
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings remains negative
Q2 FY2026 retained earnings was -$721.72M, compared with -$427.35M a year earlier.
Context
- Retained earnings amounted to 54.0% of total assets at the end of Q2 FY2026, down 10.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -68.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (561.76M) USD
- Year-over-year change
- -83.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (561.76M) | -83.6% |
| FY2024 | 2024-12-31 | (305.92M) | -147.2% |
| FY2023 | 2023-12-31 | (123.77M) | -211.1% |
| FY2022 | 2022-12-31 | (39.79M) | — |
Retained Earnings vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -68.9% is the 9th highest of 10, against a peer median of -24.7%.
- Retained earnings amounts to 54.0% of total assets for APGE, versus a peer median of 114.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥0 CNY | +100.0% | — | 0.0% |
| Sep 2026 | -$575.13M USD | -70.3% | — | 54.9% | |
| Jun 2026 | -$580.6M USD | -64.0% | — | 70.1% | |
IRONDisc Medicine, Inc. | Sep 2026 | -$692.76M USD | -54.1% | — | 99.0% |
| Jun 2026 | -$721.72M USD | -68.9% | — | 54.0% | |
| Mar 2026 | -$1.27B USD | -24.7% | — | 197.2% | |
| Sep 2026 | -$1.57B USD | -37.6% | — | 130.8% | |
| Sep 2026 | -$1.93B USD | -0.0% | — | 114.7% | |
| Jun 2026 | -$2.73B USD | -7.4% | — | 254.0% | |
| Mar 2026 | -$4.72B USD | -14.8% | — | 364.0% | |
| Peer median (excluding APGE) | — | -24.7% | — | 114.7% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.